Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3799426 | 1.00 | CNR2 (0.40) | CNR2CNR1ADORA1P2RX7MAPK8 | |
| SCHEMBL4096379 | 0.95 | CNR2 (0.41) | CNR2CNR1ADORA1P2RX7MAPK8 | |
| SCHEMBL3813611 | 0.84 | MAPK8 (0.56) | CNR2CNR1MAPK8MAPK9MAPK10 | |
| SCHEMBL4085846 | 0.84 | MAPK8 (0.56) | CNR2CNR1MAPK8MAPK9MAPK10 | |
| SCHEMBL3743041 | 0.83 | CNR2 (0.46) | CNR2CNR1ADORA1P2RX7HSD11B1 | |
| SCHEMBL3806688 | 0.83 | CNR2 (0.60) | CNR2CNR1ADORA1MAPK8MAPK9 | |
| SCHEMBL4080886 | 0.83 | CNR2 (0.60) | CNR2CNR1ADORA1MAPK8MAPK9 | |
| SCHEMBL4080526 | 0.80 | MAPK8 (0.52) | CNR2CNR1MAPK8MAPK9MAPK10 | |
| SCHEMBL4084484 | 0.79 | CNR2 (0.60) | CNR2CNR1ADORA1MAPK8MAPK9 | |
| SCHEMBL3806301 | 0.79 | CNR2 (0.60) | CNR2CNR1ADORA1MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338623-B2 | N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885ADORA1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.